Hub : Traits :

Mood swings

547 significantly associated models · 76 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	205517299	205921859	1	1	1.9e-08	1.5e-06	7.8e-01	100	SLC41A1
2	3	48381826	51043528	14	2	1.4e-12	1.5e-10	1.2e-01	94	GPX1 RBM6
3	5	147516165	148067337	1	1	1.1e-07	5.4e-09	1.5e-02	83	FBXO38
4	7	11553163	12967449	1	1	1.5e-09	3.3e-09	1.2e-01	93	TMEM106B
5	8	8092025	11860845	9	1	6.8e-10	8.5e-10	1.4e-01	94	AF131215.2
6	8	140969818	142706843	1	1	4.4e-10	7.8e-09	7.1e-01	100	PTK2
7	9	119768572	121177842	1	1	8.1e-09	1.2e-08	1.0e+00	100	TLR4
8	11	46578400	48559571	8	1	2.8e-12	1.1e-11	2.0e-01	96	MADD
9	11	112542418	113969669	4	3	1.8e-09	4.0e-13	7.3e-04	78	ANKK1 DRD2 RP11-159N11.4
10	12	121453962	122915054	1	1	1.3e-07	5.4e-09	1.2e-02	81	TMEM120B
11	14	74531485	76089054	3	1	1.5e-08	1.6e-09	3.5e-02	88	DLST
12	16	86667409	89428967	3	2	1.0e-08	1.4e-08	1.0e+00	100	FBXO31 MVD
13	17	42607368	45796313	20	1	2.6e-17	4.2e-15	5.7e-01	100	WNT3
14	18	49172179	51753106	1	1	1.5e-07	8.7e-12	3.1e-06	53	DCC
15	18	52209411	54028036	1	1	1.0e-13	1.4e-13	8.0e-02	94	TCF4
16	22	40472399	42614362	7	1	3.0e-11	2.5e-12	2.0e-02	89	SLC25A17

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder or Schizophrenia	2.74	2	1	2.2	0.00	1.0e+00	DCC SLC25A17
Depressed Affect (Nagel 2018)	16.81	17	13	28.9	0.99	8.2e-14	ANKK1 DCC DLST DRD2 FBXO31 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC41A1 TCF4 TLR4 TMEM106B TMEM120B WNT3
Depression (Nagel 2018)	7.39	6	1	2.2	0.98	3.9e-04	ANKK1 DCC MADD RP11-159N11.4 TMEM106B WNT3
Intelligence (Savage-Jansen 2018)	4.37	4	3	6.7	-0.97	3.1e-02	FBXO31 GPX1 RBM6 WNT3
Neuroticism (Nagel 2018)	16.46	17	12	26.7	0.97	6.2e-11	ANKK1 DCC DLST DRD2 FBXO31 FBXO38 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC25A17 TCF4 TLR4 TMEM106B WNT3
Schizophrenia (2018)	2.83	2	0	0.0	0.00	1.0e+00	DCC SLC25A17
Worry (Nagel 2018)	10.17	10	6	13.3	1.00	1.3e-09	ANKK1 DLST DRD2 FBXO31 FBXO38 MADD RP11-159N11.4 SLC25A17 TMEM106B WNT3
Alzheimer’s Disease (including proxy)	2.24	1	0	0.0	0.00	1.0e+00	MADD
Crohns Disease (2017)	1.77	1	1	2.2	0.00	1.0e+00	GPX1
Irritable Bowel Disease (IBD)	2.42	2	1	2.2	0.00	1.0e+00	GPX1 RBM6
Ulcerative Colitis (UC)	2.34	2	1	2.2	0.00	1.0e+00	GPX1 RBM6
Major Depression (MDD)	5.18	3	0	0.0	0.00	1.0e+00	GPX1 TCF4 TMEM106B
Reaction Time	1.98	1	0	0.0	0.00	1.0e+00	FBXO31
Verbal and Numeric Reasoning (VNR)	3.66	3	2	4.4	0.00	1.0e+00	FBXO31 GPX1 RBM6
Breast Cancer	1.85	1	1	2.2	0.00	1.0e+00	WNT3
Ovarian Cancer	2.46	1	1	2.2	0.00	1.0e+00	WNT3
Prostate Cancer	3.11	2	0	0.0	0.00	1.0e+00	GPX1 SLC41A1
Age at First Birth	4.19	2	2	4.4	0.00	1.0e+00	GPX1 RBM6
Body Mass Index (BMI) (2010)	2.56	1	0	0.0	0.00	1.0e+00	MADD
Mean Putamen Volume	2.29	1	0	0.0	0.00	1.0e+00	WNT3
Fasting Glucose	2.80	1	1	2.2	0.00	1.0e+00	MADD
Lupus	1.64	1	0	0.0	0.00	1.0e+00	AF131215.2
Neuroticism (2016)	9.90	8	2	4.4	0.98	1.9e-05	AF131215.2 DRD2 GPX1 MADD SLC25A17 TCF4 TLR4 WNT3
Primary Biliary Cirrhosis	1.51	1	0	0.0	0.00	1.0e+00	WNT3
Schizophrenia (2014)	2.85	3	0	0.0	0.00	1.0e+00	DRD2 SLC25A17 WNT3
Ulcerative Colitis	2.03	1	1	2.2	0.00	1.0e+00	GPX1
Blood Eosinophil Count	1.59	5	3	6.7	0.10	8.7e-01	FBXO38 GPX1 RBM6 SLC25A17 WNT3
Blood Platelet Count	1.59	5	3	6.7	0.48	4.1e-01	DLST MADD PTK2 TMEM120B WNT3
Blood Red Count	3.03	3	2	4.4	0.00	1.0e+00	DRD2 MVD WNT3
Blood White Count	1.41	5	3	6.7	0.41	4.9e-01	FBXO38 GPX1 MADD RBM6 WNT3
Heel T-Score	1.42	6	2	4.4	-0.26	6.2e-01	DLST MADD RBM6 SLC25A17 TMEM120B WNT3
BMI	3.86	7	3	6.7	0.52	2.3e-01	ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TLR4 TMEM120B
Height	1.55	9	9	20.0	-0.29	4.5e-01	DCC GPX1 MADD MVD SLC41A1 TCF4 TMEM106B TMEM120B WNT3
Waist Hip Ratio (WHR)	2.17	4	2	4.4	0.15	8.5e-01	GPX1 PTK2 RP11-159N11.4 WNT3
Systolic Blood Pressure	2.39	4	2	4.4	0.81	1.9e-01	FBXO38 GPX1 MADD PTK2
Smoking Status	3.38	4	1	2.2	-0.78	2.2e-01	FBXO31 GPX1 TMEM120B WNT3
Allergy or Eczema	1.26	1	1	2.2	0.00	1.0e+00	SLC25A17
Cardiovascular Disease	2.24	2	0	0.0	0.00	1.0e+00	DRD2 RP11-159N11.4
Respiratory disease	2.19	2	0	0.0	0.00	1.0e+00	MVD RBM6
Type 2 Diabetes (T2D) (2018)	2.16	1	0	0.0	0.00	1.0e+00	RBM6
Lung FEV1/FVC ratio	5.37	4	2	4.4	-0.80	2.0e-01	DLST FBXO38 PTK2 SLC41A1
Lung FVC	4.29	7	3	6.7	-0.75	5.2e-02	DCC FBXO38 GPX1 MVD RBM6 TCF4 WNT3
Neuroticism	16.53	17	14	31.1	0.98	1.7e-11	ANKK1 DLST DRD2 FBXO31 FBXO38 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC25A17 SLC41A1 TCF4 TLR4 TMEM106B WNT3
Chronotype (morning person)	1.61	1	0	0.0	0.00	1.0e+00	RP11-159N11.4
Hair Pigment	0.46	5	2	4.4	0.61	2.7e-01	FBXO31 MVD SLC25A17 SLC41A1 WNT3
Tanning	0.45	1	0	0.0	0.00	1.0e+00	MVD
Hand grip strength (left)	3.51	4	4	8.9	-0.66	3.4e-01	MADD SLC41A1 TCF4 WNT3
Number of treatments/medications taken	4.67	3	2	4.4	0.00	1.0e+00	DLST GPX1 RBM6
Sensitivity / hurt feelings	8.73	7	4	8.9	0.99	3.4e-05	AF131215.2 ANKK1 DRD2 FBXO31 PTK2 RP11-159N11.4 WNT3
Frequency of depressed mood in last 2 weeks	8.43	6	0	0.0	0.99	7.0e-05	AF131215.2 ANKK1 DRD2 MADD TMEM106B WNT3
Hearing difficulty/problems: Yes	1.67	1	0	0.0	0.00	1.0e+00	PTK2
Relative age of first facial hair	4.10	2	1	2.2	0.00	1.0e+00	RBM6 WNT3
Systolic blood pressure, automated reading	2.80	4	3	6.7	0.59	4.1e-01	AF131215.2 FBXO38 GPX1 MADD
Medication: Co-codamol	2.23	1	0	0.0	0.00	1.0e+00	RBM6
Pack years adult smoking proportion	2.58	1	0	0.0	0.00	1.0e+00	GPX1
Impedance of leg (right)	2.72	5	4	8.9	-0.10	8.8e-01	AF131215.2 GPX1 MADD RBM6 SLC41A1
Leg fat-free mass (left)	2.10	5	3	6.7	0.21	7.4e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Trunk fat percentage	3.64	8	3	6.7	0.02	9.6e-01	ANKK1 FBXO31 GPX1 MADD RBM6 SLC25A17 TMEM120B WNT3
Hand grip strength (right)	2.96	4	3	6.7	-0.61	3.9e-01	MADD SLC41A1 TCF4 WNT3
Current tobacco smoking	3.28	1	0	0.0	0.00	1.0e+00	SLC25A17
Fed-up feelings	11.14	12	7	15.6	0.99	5.7e-09	AF131215.2 DCC DLST DRD2 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 TLR4 WNT3
Frequency of unenthusiasm / disinterest in last 2 weeks	7.20	5	0	0.0	0.97	5.7e-03	ANKK1 DCC DRD2 GPX1 RP11-159N11.4
Relative age voice broke	2.20	1	1	2.2	0.00	1.0e+00	WNT3
Taking other prescription medications	5.69	4	1	2.2	0.99	6.4e-03	DLST GPX1 RBM6 TMEM120B
Age when periods started (menarche)	3.45	3	2	4.4	0.00	1.0e+00	GPX1 MADD SLC41A1
Heel bone mineral density (BMD) T-score, automated (left)	2.94	1	1	2.2	0.00	1.0e+00	AF131215.2
Qualifications: CSEs or equivalent	2.06	1	0	0.0	0.00	1.0e+00	WNT3
High blood pressure	2.66	2	2	4.4	0.00	1.0e+00	AF131215.2 MADD
Sitting height	2.77	5	5	11.1	-0.37	5.4e-01	DCC FBXO31 MADD SLC41A1 WNT3
Body mass index (BMI)	4.65	5	4	8.9	0.30	6.2e-01	AF131215.2 GPX1 MADD RBM6 TMEM120B
Impedance of leg (left)	2.70	6	3	6.7	-0.13	8.1e-01	AF131215.2 GPX1 MADD RBM6 SLC41A1 WNT3
Leg predicted mass (left)	2.11	5	3	6.7	0.21	7.4e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Trunk fat mass	3.64	7	4	8.9	0.20	6.6e-01	ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B WNT3
Waist circumference	3.33	5	3	6.7	0.55	3.4e-01	ANKK1 MADD RBM6 RP11-159N11.4 TMEM120B
Number of incorrect matches in round	2.64	1	0	0.0	0.00	1.0e+00	SLC41A1
Past tobacco smoking	2.03	1	0	0.0	0.00	1.0e+00	WNT3
Nervous feelings	8.16	7	3	6.7	0.98	1.0e-04	AF131215.2 ANKK1 DLST FBXO38 MADD SLC25A17 WNT3
Frequency of tenseness / restlessness in last 2 weeks	8.01	7	1	2.2	1.00	2.4e-06	ANKK1 DRD2 GPX1 MADD RBM6 TMEM106B WNT3
Hearing difficulty/problems with background noise	3.30	2	0	0.0	0.00	1.0e+00	SLC41A1 WNT3
Hair/balding pattern: Pattern 2	2.72	1	1	2.2	0.00	1.0e+00	WNT3
Forced vital capacity (FVC)	3.66	2	2	4.4	0.00	1.0e+00	GPX1 WNT3
Heel bone mineral density (BMD) T-score, automated (right)	3.00	1	1	2.2	0.00	1.0e+00	AF131215.2
Ever unenthusiastic/disinterested for a whole week	4.09	2	0	0.0	0.00	1.0e+00	RBM6 WNT3
Qualifications: None of the above	3.87	3	2	4.4	0.00	1.0e+00	GPX1 RBM6 TMEM120B
Financial difficulties in last 2 years	4.03	2	0	0.0	0.00	1.0e+00	DRD2 TMEM106B
Mouth/teeth dental problems	2.42	1	0	0.0	0.00	1.0e+00	WNT3
Diabetes (self-reported)	2.00	1	0	0.0	0.00	1.0e+00	RBM6
Fluid intelligence score	3.50	4	1	2.2	-0.51	4.9e-01	GPX1 MADD RBM6 TMEM120B
Neuroticism score	18.40	19	13	28.9	0.98	1.2e-12	AF131215.2 ANKK1 DCC DLST DRD2 FBXO31 FBXO38 GPX1 MADD MVD PTK2 RBM6 RP11-159N11.4 SLC25A17 SLC41A1 TCF4 TLR4 TMEM106B WNT3
Weight	3.04	7	3	6.7	0.41	3.7e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 SLC41A1 TMEM120B
Impedance of arm (right)	4.10	6	4	8.9	-0.45	3.7e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM106B WNT3
Arm fat percentage (right)	3.94	7	3	6.7	0.33	4.7e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Trunk fat-free mass	1.58	3	2	4.4	0.00	1.0e+00	AF131215.2 RBM6 SLC41A1
Hip circumference	2.88	5	3	6.7	0.34	5.7e-01	AF131215.2 GPX1 MADD RBM6 TMEM120B
Time employed in main current job	2.49	1	1	2.2	0.00	1.0e+00	WNT3
Alcohol intake versus 10 years previously	2.60	1	0	0.0	0.00	1.0e+00	RBM6
Father's age at death	2.50	1	0	0.0	0.00	1.0e+00	GPX1
Worrier / anxious feelings	9.43	6	5	11.1	0.95	3.3e-03	AF131215.2 DLST SLC25A17 TCF4 TLR4 WNT3
Frequency of tiredness / lethargy in last 2 weeks	6.00	4	0	0.0	0.86	1.4e-01	DCC GPX1 PTK2 TMEM106B
Hair/balding pattern: Pattern 3	5.01	1	1	2.2	0.00	1.0e+00	WNT3
Number of live births	1.90	2	0	0.0	0.00	1.0e+00	RBM6 WNT3
Forced expiratory volume in 1-second (FEV1)	5.12	3	3	6.7	0.00	1.0e+00	FBXO38 GPX1 WNT3
Qualifications: A levels/AS levels or equivalent	4.43	3	2	4.4	0.00	1.0e+00	GPX1 RBM6 TMEM120B
Mouth/teeth dental problems: Dentures	2.30	2	0	0.0	0.00	1.0e+00	GPX1 RBM6
Asthma	2.20	2	0	0.0	0.00	1.0e+00	MVD RBM6
Depression (self-reported)	3.93	1	0	0.0	0.00	1.0e+00	TMEM106B
Forced expiratory volume in 1-second (FEV1), Best measure	5.31	4	3	6.7	-0.94	6.4e-02	FBXO38 GPX1 MVD WNT3
Impedance of arm (left)	4.04	5	4	8.9	-0.53	3.6e-01	AF131215.2 GPX1 RBM6 TMEM106B WNT3
Arm fat mass (right)	4.11	7	4	8.9	0.39	3.8e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Trunk predicted mass	1.58	3	2	4.4	0.00	1.0e+00	AF131215.2 RBM6 SLC41A1
Standing height	1.67	5	4	8.9	-0.58	3.1e-01	GPX1 MADD SLC41A1 TMEM106B WNT3
Exposure to tobacco smoke at home	2.07	1	0	0.0	0.00	1.0e+00	RBM6
Tense / 'highly strung'	7.76	6	2	4.4	0.99	1.8e-04	AF131215.2 ANKK1 DRD2 RP11-159N11.4 SLC25A17 TMEM106B
Seen doctor (GP) for nerves, anxiety, tension or depression	7.34	5	3	6.7	0.98	3.6e-03	ANKK1 DRD2 GPX1 TCF4 TMEM106B
Hair/balding pattern: Pattern 4	5.96	1	1	2.2	0.00	1.0e+00	WNT3
Peak expiratory flow (PEF)	4.50	4	3	6.7	-0.69	3.1e-01	AF131215.2 FBXO38 SLC41A1 WNT3
Ever highly irritable/argumentative for 2 days	4.35	1	1	2.2	0.00	1.0e+00	RBM6
Qualifications: O levels/GCSEs or equivalent	2.42	1	1	2.2	0.00	1.0e+00	GPX1
Medication: Paracetamol	4.11	2	2	4.4	0.00	1.0e+00	GPX1 WNT3
Headache pain in last month	4.35	2	1	2.2	0.00	1.0e+00	TLR4 WNT3
Hypothyroidism/myxoedema (self-reported)	2.02	1	0	0.0	0.00	1.0e+00	AF131215.2
Birth weight	1.47	1	0	0.0	0.00	1.0e+00	SLC41A1
Chronic bronchitis/emphysema (mother)	2.66	1	0	0.0	0.00	1.0e+00	RBM6
High blood pressure (siblings)	1.80	1	0	0.0	0.00	1.0e+00	TMEM106B
Forced vital capacity (FVC), Best measure	3.93	3	2	4.4	0.00	1.0e+00	FBXO38 GPX1 WNT3
Body fat percentage	3.74	7	3	6.7	0.21	6.6e-01	ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B WNT3
Leg fat percentage (right)	3.98	4	3	6.7	0.54	4.6e-01	ANKK1 GPX1 MADD RBM6
Arm fat-free mass (right)	2.22	5	3	6.7	0.27	6.6e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Exposure to tobacco smoke outside home	2.52	1	0	0.0	0.00	1.0e+00	RBM6
Comparative body size at age 10	3.51	3	2	4.4	0.00	1.0e+00	AF131215.2 MADD SLC41A1
Number of full brothers	3.27	1	0	0.0	0.00	1.0e+00	WNT3
Worry too long after embarrassment	6.10	5	2	4.4	0.97	6.6e-03	AF131215.2 ANKK1 DRD2 RP11-159N11.4 WNT3
Seen a psychiatrist for nerves, anxiety, tension or depression	5.21	1	0	0.0	0.00	1.0e+00	TMEM106B
Wheeze or whistling in the chest in last year	4.31	3	1	2.2	0.00	1.0e+00	GPX1 MVD RBM6
Age at first live birth	4.37	2	2	4.4	0.00	1.0e+00	GPX1 RBM6
Health satisfaction	4.19	2	0	0.0	0.00	1.0e+00	DRD2 GPX1
Qualifications: College or University degree	5.33	4	3	6.7	-0.96	3.7e-02	FBXO31 GPX1 RBM6 WNT3
Emphysema/chronic bronchitis	3.16	1	0	0.0	0.00	1.0e+00	WNT3
Medication for pain relief, constipation, heartburn	3.54	3	1	2.2	0.00	1.0e+00	DLST GPX1 WNT3
Neck or shoulder pain in last month	2.65	2	0	0.0	0.00	1.0e+00	GPX1 PTK2
Medication: Seretide 50 evohaler	2.01	1	0	0.0	0.00	1.0e+00	RBM6
Mean time to correctly identify matches	2.24	2	0	0.0	0.00	1.0e+00	FBXO31 SLC41A1
Whole body fat mass	3.98	6	4	8.9	0.55	2.6e-01	ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Leg fat mass (right)	4.34	7	3	6.7	0.47	2.9e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Arm predicted mass (right)	2.26	5	3	6.7	0.25	6.8e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Alcohol intake frequency.	4.89	7	3	6.7	0.29	5.3e-01	DCC DRD2 MADD RBM6 RP11-159N11.4 TCF4 WNT3
Comparative height size at age 10	2.36	5	4	8.9	-0.59	3.0e-01	DLST GPX1 SLC41A1 TCF4 WNT3
Suffer from 'nerves'	8.30	6	3	6.7	0.97	1.2e-03	AF131215.2 ANKK1 DLST DRD2 MADD WNT3
Overall health rating	6.61	7	3	6.7	0.98	1.6e-04	ANKK1 FBXO38 GPX1 PTK2 RBM6 RP11-159N11.4 TMEM120B
Chest pain or discomfort	2.63	1	0	0.0	0.00	1.0e+00	GPX1
Age at last live birth	4.56	2	2	4.4	0.00	1.0e+00	GPX1 RBM6
Leg pain on walking	2.68	1	0	0.0	0.00	1.0e+00	WNT3
Supplements: Vitamin C	1.59	1	0	0.0	0.00	1.0e+00	WNT3
Hypertension (Self-reported)	2.49	2	1	2.2	0.00	1.0e+00	AF131215.2 MADD
Illnesses of father: Heart disease	1.57	1	0	0.0	0.00	1.0e+00	WNT3
Whole body fat-free mass	1.82	5	3	6.7	0.21	7.4e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Leg fat-free mass (right)	2.09	4	3	6.7	0.18	8.2e-01	AF131215.2 RBM6 SLC41A1 TMEM120B
Arm fat percentage (left)	4.03	6	3	6.7	0.28	5.8e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 TMEM120B
Average weekly red wine intake	2.30	1	0	0.0	0.00	1.0e+00	RBM6
Handedness (chirality/laterality): Left-handed	2.76	1	1	2.2	0.00	1.0e+00	WNT3
Loneliness, isolation	7.25	5	2	4.4	0.98	2.9e-03	GPX1 MADD RP11-159N11.4 TMEM106B WNT3
Diabetes diagnosed by doctor	2.31	1	0	0.0	0.00	1.0e+00	RBM6
Mouth/teeth dental problems: Mouth ulcers	2.60	1	1	2.2	0.00	1.0e+00	WNT3
Back pain experienced in last month	2.58	1	0	0.0	0.00	1.0e+00	PTK2
Asthma (self-reported)	2.28	2	0	0.0	0.00	1.0e+00	MVD RBM6
Forced expiratory volume in 1-second (FEV1), predicted percentage	4.10	2	2	4.4	0.00	1.0e+00	FBXO38 WNT3
Whole body water mass	1.85	5	3	6.7	0.21	7.3e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Leg predicted mass (right)	2.06	4	3	6.7	0.18	8.2e-01	AF131215.2 RBM6 SLC41A1 TMEM120B
Arm fat mass (left)	4.13	7	4	8.9	0.38	4.0e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Number of self-reported non-cancer illnesses	3.87	1	0	0.0	0.00	1.0e+00	TMEM106B
Average weekly champagne plus white wine intake	2.46	1	0	0.0	0.00	1.0e+00	WNT3
Miserableness	13.84	10	8	17.8	0.98	6.8e-07	AF131215.2 ANKK1 DRD2 GPX1 MADD RBM6 RP11-159N11.4 TCF4 TMEM106B WNT3
Guilty feelings	9.60	7	4	8.9	0.98	1.4e-04	AF131215.2 ANKK1 DLST DRD2 MADD RP11-159N11.4 WNT3
Financial situation satisfaction	4.48	1	1	2.2	0.00	1.0e+00	GPX1
Medication: Blood pressure	1.75	1	0	0.0	0.00	1.0e+00	AF131215.2
Medication: Bendroflumethiazide	2.35	2	0	0.0	0.00	1.0e+00	AF131215.2 MADD
Medication: Paracetamol	4.11	2	1	2.2	0.00	1.0e+00	GPX1 WNT3
Illnesses of father: High blood pressure	1.68	1	0	0.0	0.00	1.0e+00	MADD
Basal metabolic rate	2.10	5	3	6.7	0.27	6.6e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Leg fat percentage (left)	4.21	5	3	6.7	0.56	3.2e-01	ANKK1 GPX1 MADD RBM6 TMEM120B
Arm fat-free mass (left)	2.33	5	3	6.7	0.32	6.0e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B
Number of operations (self-reported)	3.50	2	0	0.0	0.00	1.0e+00	GPX1 RBM6
Average weekly beer plus cider intake	3.47	2	1	2.2	0.00	1.0e+00	AF131215.2 RBM6
Irritability	10.31	10	4	8.9	0.97	2.2e-06	AF131215.2 ANKK1 DRD2 GPX1 MVD SLC25A17 TCF4 TLR4 TMEM106B WNT3
Risk taking	1.89	1	0	0.0	0.00	1.0e+00	AF131215.2
Fractured/broken bones in last 5 years	1.55	1	0	0.0	0.00	1.0e+00	WNT3
Diastolic blood pressure, automated reading	2.24	4	1	2.2	0.49	5.1e-01	AF131215.2 GPX1 MADD RBM6
Ever depressed for a whole week	3.91	1	0	0.0	0.00	1.0e+00	RBM6
Vascular/heart problems diagnosed by doctor	2.50	2	1	2.2	0.00	1.0e+00	AF131215.2 MADD
Pain experienced in last month	3.96	4	1	2.2	-0.97	2.9e-02	GPX1 MVD PTK2 WNT3
Pack years of smoking	2.52	1	0	0.0	0.00	1.0e+00	GPX1
Impedance of whole body	3.60	5	4	8.9	-0.42	4.8e-01	AF131215.2 GPX1 RBM6 SLC41A1 WNT3
Leg fat mass (left)	4.55	7	5	11.1	0.46	2.9e-01	AF131215.2 ANKK1 GPX1 MADD RBM6 RP11-159N11.4 TMEM120B
Arm predicted mass (left)	2.36	5	4	8.9	0.29	6.4e-01	AF131215.2 GPX1 RBM6 SLC41A1 TMEM120B

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	12	0.344	1.8
GTEx	Adipose Visceral Omentum	11	0.540	2.0
GTEx	Adrenal Gland	8	0.549	1.9
GTEx	Artery Aorta	12	0.403	2.0
GTEx	Artery Coronary	10	0.845	2.1
GTEx	Artery Tibial	8	0.213	1.8
GTEx	Brain Caudate basal ganglia	7	0.761	2.0
GTEx	Brain Cerebellar Hemisphere	10	0.672	1.9
GTEx	Brain Cerebellum	12	0.605	1.9
GTEx	Brain Cortex	10	0.966	2.1
GTEx	Brain Frontal Cortex BA9	6	0.649	2.0
GTEx	Brain Hippocampus	4	0.763	2.1
GTEx	Brain Hypothalamus	5	0.847	2.1
GTEx	Brain Nucleus accumbens basal ganglia	7	0.809	2.0
GTEx	Brain Putamen basal ganglia	4	0.641	2.1
GTEx	Breast Mammary Tissue	9	0.456	1.9
GTEx	Breast Mammary Tissue (Male)	7	0.587	2.0
GTEx	Breast Mammary Tissue (Female)	9	0.547	2.0
GTEx	Cells EBV-transformed lymphocytes	12	0.843	2.1
GTEx	Cells Transformed fibroblasts	11	0.262	1.8
GTEx	Colon Sigmoid	10	0.684	2.0
GTEx	Colon Transverse	10	0.484	1.9
GTEx	Esophagus Gastroesophageal Junction	10	0.692	2.0
GTEx	Esophagus Mucosa	16	0.482	1.9
GTEx	Esophagus Muscularis	17	0.526	2.0
GTEx	Heart Atrial Appendage	8	0.507	1.9
GTEx	Heart Left Ventricle	9	0.588	2.0
GTEx	Liver	4	0.558	2.0
GTEx	Lung	13	0.452	1.9
GTEx	Muscle Skeletal	10	0.346	1.8
GTEx	Nerve Tibial	12	0.278	1.8
GTEx	Ovary	7	0.771	2.2
GTEx	Pancreas	9	0.551	1.9
GTEx	Pituitary	6	0.538	2.0
GTEx	Prostate	7	0.838	2.0
GTEx	Skin Not Sun Exposed Suprapubic	12	0.488	2.0
GTEx	Skin Sun Exposed Lower leg	15	0.412	1.9
GTEx	Small Intestine Terminal Ileum	4	0.868	2.2
GTEx	Spleen	9	0.638	2.0
GTEx	Stomach	9	0.619	2.0
GTEx	Testis	11	0.349	1.9
GTEx	Thyroid	16	0.400	1.8
GTEx	Uterus	8	1.411	2.4
GTEx	Vagina	6	0.945	2.0
GTEx	Whole Blood	6	0.301	1.8
METSIM	Adipose	4	0.087	1.7
NTR	Blood	8	0.333	1.7
ROSMAP	Brain Pre-frontal Cortex	5	0.114	1.7
YFS	Blood	7	0.152	1.6
CommonMind	Brain Pre-frontal Cortex	6	0.112	1.7
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.7
The Cancer Genome Atlas	Breast Invasive Carcinoma	5	0.113	1.6
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.273	1.8
The Cancer Genome Atlas	Colon Adenocarcinoma	4	0.194	1.8
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.438	2.0
The Cancer Genome Atlas	Glioblastoma Multiforme	4	0.391	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	7	0.257	1.8
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	6	0.146	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	3	0.146	1.8
The Cancer Genome Atlas	Brain Lower Grade Glioma	4	0.093	1.6
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	8	0.272	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	6	0.239	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	5	0.314	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	3	0.181	1.8
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	3	0.226	1.8
The Cancer Genome Atlas	Prostate Adenocarcinoma	8	0.173	1.6
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.289	1.7
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.281	1.7
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.6
The Cancer Genome Atlas	Stomach Adenocarcinoma	5	0.297	1.8
The Cancer Genome Atlas	Testicular Germ Cell Tumors	4	0.313	1.7
The Cancer Genome Atlas	Thyroid Carcinoma	6	0.116	1.6
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.394	1.8